FIELD: medicine.
SUBSTANCE: claimed composition contains core including Rabeprasol or pharmaceutically acceptable salt thereof as acid secretion inhibitor in stomach and basic compound, intermediate coat coating the core, and overcoat applied on intermediate layer and containing water insoluble polymer and enterosoluble polymer. Also described is method for production of composition containing said preparation.
EFFECT: composition of prolonged storage time providing effective concentration of Rabeprasol in blood for long period of time.
16 cl, 5 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF CONTROLLED RELEASE AND METHOD OF PRODUCTION THEREOF | 2005 |
|
RU2337687C2 |
| PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
| METHODS FOR STABILIZING BENZIMIDAZOLE-BASE COMPOUNDS | 2000 |
|
RU2259828C2 |
| CONTROLLED RELEASE SOLID PREPARATION | 2006 |
|
RU2496480C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF GASTRIC AND DUODENUM ULCER IN FORM OF SOLID GELATIN CAPSULES, WHICH CONTAINS RABEPRAZOLE OR ITS DERIVATIVES, AND METHOD OF ITS OBTAINING | 2007 |
|
RU2414889C2 |
| MEDICINAL AGENT LAMOTRIGIN WITH REGULATED RELEASE | 2003 |
|
RU2328274C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| ORAL PHARMACEUTICAL MEDICINAL FORM WITH DISCRETE RELEASE | 1998 |
|
RU2205028C2 |
| PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
